At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Market Closed 04-04 16:00:00 EDT
294.39
-15.46
-4.99%
盘后294.00
-0.39-0.13%
19:40 EDT
High312.11Low293.72Vol5.25M
Open312.11D1 Closing309.85Amplitude5.94%
Mkt Cap158.15BTradable Cap157.70BTotal Shares537.20M
T/O1.57BT/O Rate0.98%Tradable Shares535.68M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Loading ...
Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease
Simply Wall St.  ·  04-04 17:34
Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
Zacks  ·  04-04 17:10
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
The Dow Needs A Refresh. These New Members Could Make It Sing. -- Barrons.com
Dow Jones  ·  04-04 16:42
The Dow Needs A Refresh. These New Members Could Make It Sing. -- Barrons.com
Shares of Some U.S. Drugmakers Down After Trump Says Pharmaceutical Sector Is 'Under Review' for Tariffs
THOMSON REUTERS  ·  04-04 13:33
Shares of Some U.S. Drugmakers Down After Trump Says Pharmaceutical Sector Is 'Under Review' for Tariffs
Amgen Says Uplizna Wins US FDA Approval for IgG4-related Disease
MT Newswires Live  ·  04-04 12:20
Amgen Says Uplizna Wins US FDA Approval for IgG4-related Disease
BUZZ-US drugmakers fall after Trump's new tariff warnings
Reuters  ·  04-04 12:16
BUZZ-US drugmakers fall after Trump's new tariff warnings
11 Stocks to Buy After the Biotech Bloodbath -- Barrons.com
Dow Jones  ·  04-04 05:00
11 Stocks to Buy After the Biotech Bloodbath -- Barrons.com
BRIEF-Amgen Uplizna Wholesale Acquisition Cost Or U.S. List Price Is $140,248.50 Per Dose (3 Vials)
Reuters  ·  04-03 21:40
BRIEF-Amgen Uplizna Wholesale Acquisition Cost Or U.S. List Price Is $140,248.50 Per Dose (3 Vials)
Amgen Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains
Dow Jones  ·  04-03 20:34
Amgen Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains
Amgen: Uplizna Wholesale Acquisition Cost or U.S. List Price Is $140,248.50 per Dose (3 Vials)
THOMSON REUTERS  ·  04-03 20:13
Amgen: Uplizna Wholesale Acquisition Cost or U.S. List Price Is $140,248.50 per Dose (3 Vials)
FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna
Dow Jones  ·  04-03 20:10
FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna
Amgen announces FDA approval of Uplizna
TIPRANKS  ·  04-03 19:40
Amgen announces FDA approval of Uplizna
Uplizna® (Inebilizumab-Cdon) Is NOW the First and Only FDA-Approved Treatment for Igg4-Related Disease
THOMSON REUTERS  ·  04-03 19:35
Uplizna® (Inebilizumab-Cdon) Is NOW the First and Only FDA-Approved Treatment for Igg4-Related Disease
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
PR Newswire  ·  04-03 19:35
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
Reuters  ·  04-03 18:56
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
US FDA approves expanded use of Amgen's rare disease drug
Reuters  ·  04-03 18:48
US FDA approves expanded use of Amgen's rare disease drug
BRIEF-FDA Approves Amgen's Uplizna For Treatment Of Immunoglobulin G4-Related Disease In Adult Patients
Reuters  ·  04-03 18:47
BRIEF-FDA Approves Amgen's Uplizna For Treatment Of Immunoglobulin G4-Related Disease In Adult Patients
FDA Approves Amgen's Uplizna for Treatment of Immunoglobulin G4-Related Disease in Adult Patients - Website
THOMSON REUTERS  ·  04-03 18:46
FDA Approves Amgen's Uplizna for Treatment of Immunoglobulin G4-Related Disease in Adult Patients - Website
BUZZ-US drugmakers rise on reprieve from Trump tariffs
Reuters  ·  04-03 13:52
BUZZ-US drugmakers rise on reprieve from Trump tariffs
Shares of US Drugmakers Rise After Tariff Exemption
THOMSON REUTERS  ·  04-03 13:35
Shares of US Drugmakers Rise After Tariff Exemption

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--
Invest in Global Markets with Tiger Brokers!
Open App